Literature DB >> 10399070

Potential strategies utilised by papillomavirus to evade host immunity.

I H Frazer1, R Thomas, J Zhou, G R Leggatt, L Dunn, N McMillan, R W Tindle, L Filgueira, P Manders, P Barnard, M Sharkey.   

Abstract

The co-evolution of papillomaviruses (PV) and their mammalian hosts has produced mechanisms by which PV might avoid specific and non-specific host immune responses. Low level expression of PV proteins in infected basal epithelial cells, together with an absence of inflammation and of virus-induced cell lysis, restricts the opportunity for effective PV protein presentation to immunocytes by dendritic cells. Additionally, PV early proteins, by a range of mechanisms, may restrict the efficacy of antigen presentation by these cells. Should an immune response be induced to PV antigens, resting keratinocytes (KC) appear resistant to interferon-gamma-enhanced mechanisms of cytotoxic T-lymphocyte (CTL)-mediated lysis, and expression of PV antigens by resting KC can tolerise PV-specific CTL. Thus, KC, in the absence of inflammation, may represent an immunologically privileged site for PV infection. Together, these mechanisms play a part in allowing persistence of PV-induced proliferative skin lesions for months to years, even in immunocompetent hosts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399070     DOI: 10.1111/j.1600-065x.1999.tb01288.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  16 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Genomic location and characterisation of nonclassical MHC class I genes in cattle.

Authors:  James Birch; Gemma Codner; Efrain Guzman; Shirley A Ellis
Journal:  Immunogenetics       Date:  2008-04-23       Impact factor: 2.846

Review 3.  [Prophylactic and therapeutic vaccines against human papilloma virus].

Authors:  A E Albers; T K Hoffmann; J P Klussmann; A M Kaufmann
Journal:  HNO       Date:  2010-08       Impact factor: 1.284

4.  Expression of CD40 and CD40L on peripheral blood mononuclear cells in patients with condyloma acuminatum.

Authors:  Dongxian Liu; Wen Jiang; Xingping Chen; Yingling Chen; Dongliang Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

5.  Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.

Authors:  Rongcun Yang; Cosette M Wheeler; Xiaojiang Chen; Satoshi Uematsu; Kiyoshi Takeda; Shizuo Akira; Diana V Pastrana; Raphael P Viscidi; Richard B S Roden
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 6.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.

Authors:  Katja Nilges; Hanni Höhn; Henryk Pilch; Claudia Neukirch; Kirsten Freitag; P J Talbot; Markus J Maeurer
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

8.  Development of a PCR assay to detect papillomavirus infection in the snow leopard.

Authors:  Katherine Mitsouras; Erica A Faulhaber; Gordon Hui; Janis O Joslin; Curtis Eng; Margaret C Barr; Kristopher Jl Irizarry
Journal:  BMC Vet Res       Date:  2011-07-18       Impact factor: 2.741

Review 9.  Arsenic toxicology: translating between experimental models and human pathology.

Authors:  J Christopher States; Aaron Barchowsky; Iain L Cartwright; John F Reichard; Bernard W Futscher; R Clark Lantz
Journal:  Environ Health Perspect       Date:  2011-06-17       Impact factor: 9.031

10.  High level expression of human epithelial beta-defensins (hBD-1, 2 and 3) in papillomavirus induced lesions.

Authors:  Kong T Chong; Liangbin Xiang; Xiaohong Wang; Eunjoo L Jun; Long-Fu Xi; John M Schweinfurth
Journal:  Virol J       Date:  2006-09-08       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.